Article

Preclinical Prediction of Resistance and Optimization of Sequential Therapy for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors

2025-05-29

Abstract excerpt

<h4>Background</h4> Anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 5% of non-small cell lung cancers (NSCLCs). Although ALK tyrosine kinase inhibitors provide substantial clinical benefits, acquired resistance-conferring mutations frequently emerge, leading to disease progression. Preclinical prediction of these mutations might help guide the development of more effective sequential t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d9943e9f-5cb1-578e-b273-d24d1a13f905
DOI: 10.1101/2025.05.26.656085

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical Prediction of Resistance and Optimization of Sequential Therapy for ALK-positive Lung Cancer Using Next-generation ALK InhibitorsDOI 10.1101/2025.05.26.656085Read

Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.Semantic proximity Read

Prediction of Resistant Mutations against Upcoming ALK-TKIs, Repotrectinib (TPX-0005) and Ensartinib (X-396)Semantic proximity Read

Identification of Mechanisms of Resistance to ALK Inhibitors. Next-generation sequencing-based liquid biopsy profiling: A step towards personalized treatment.Semantic proximity Read

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Semantic proximity Read

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.Semantic proximity Read

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patientsSemantic proximity Read

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversitySemantic proximity Read

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.Semantic proximity Read

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read